This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Dexcom can amend counterclaim after Abbott partially withdrew infringement claim, UPC The Hague says

( September 17, 2024, 15:00 GMT | Official Statement) -- MLex Summary: Dexcom can amend its counterclaim in its dispute with Abbott over European Patent 4,070,727, the Unified Patent Court’s Local Division in The Hague said in an order published today. Dexcom seeks a declaration of non-infringement for its G7-System when used with the G7-Receiver, following Abbott’s partial withdrawal of its infringement claim. Dexcom could not have anticipated the withdrawal earlier, the court said, deeming the amendment request timely and procedurally fair. Abbot now has 30 days in which to respond.Court documents attached...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login